Drug Price Cap to Impact Glaxo, Sanofi, Novartis most: Prabhudas Lilladher

  • 10:28
  • Published On: July 15, 2014
Cinema View
Embed

Surjit Pal, pharma analyst at Prabhudas Lilladher says the government's move to cap prices of essential drugs is justified, but it will impact MNC pharma companies more as most domestic drugmakers have already de-risked their overall portfolio by venturing into export market.

Advertisement

Related Videos

Regulatory Environment Unfavourable For Pharma Companies: Surjit Pal
May 23, 2017 9:10
Bearish On Large Cap Pharma Stocks: Surjit Pal
November 04, 2016 4:17
Underweight on Pharma Stocks for 2016: Surjit Pal
January 04, 2016 9:20
Glenmark Among Top Pharma Picks: Prabhudas Lilladher
October 28, 2015 13:26
Generic Nexium to Boost Dr Reddy's Bottlomline: Surjit Pal
September 28, 2015 10:31
'New Drug Approvals to Grow from Second Half of FY16'
June 23, 2015 9:35
Don't See Much Downside in Lupin: Prabhudas Lilladher
May 13, 2015 4:03
Bullish on Sun Pharma: Prabhudas Lilladher
September 29, 2014 11:06
Buy Ranbaxy if it falls below Rs 250: Surjit Pal
January 24, 2014 6:41
Ranbaxy Mohali unit to face headwinds for a year: Surjit Pal
September 18, 2013 7:55
Sun Pharma, Ranbaxy based on macro, company-specific triggers: Surjit Pal
June 04, 2013 4:42
Our Offerings: NDTV
  • मध्य प्रदेश
  • राजस्थान
  • इंडिया
  • मराठी
  • 24X7
Choose Your Destination